Cargando…
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Glioblastoma (GBM) is the most common, and aggressive, primary brain tumor in adults. With a median patient survival of less than two years, GBM represents one of the biggest therapeutic challenges of the modern era. Even with the best available treatment, recurrence rates are nearly 100% and therap...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710964/ https://www.ncbi.nlm.nih.gov/pubmed/29207684 http://dx.doi.org/10.18632/oncotarget.21586 |